Standard BioTools Expects 2025 Revenue to Exceed Guidance and Targets Profitability
I'm PortAI, I can summarize articles.
Standard BioTools Inc. announced that it expects 2025 revenue to exceed guidance, with fourth quarter revenue of approximately $56 million and full year revenue around $185 million. The company surpassed its expectations for both combined and continuing operations, attributing this success to organizational streamlining and cost structure improvements. Looking ahead, Standard BioTools anticipates having about $550 million in cash after the sale of SomaLogic and aims for positive adjusted EBITDA in 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments